Vertex Pharmaceuticals Stock

Vertex Pharmaceuticals Debt 2024

Vertex Pharmaceuticals Debt

-10,791.6 USD

Ticker

VRTX

ISIN

US92532F1003

WKN

882807

In 2024, Vertex Pharmaceuticals's total debt was -10,791.6 USD, a 7.57% change from the -10,032 USD total debt recorded in the previous year.

Vertex Pharmaceuticals Aktienanalyse

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching, developing, and marketing therapies for rare diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA. Since its inception, Vertex has been dedicated to pushing the boundaries of science to develop groundbreaking therapies for diseases such as cystic fibrosis and other rare genetic disorders. The company's history began in 1989 when Joshua Boger, a former employee of Merck & Co., founded the company with the goal of becoming a leading developer of therapies for rare diseases. In 1993, Vertex went public, achieving significant success. In 2012, the company announced the development of the first approved therapy for the treatment of cystic fibrosis, Kalydeco. Since then, Vertex has expanded its technology and production capabilities and continues to work on developing additional therapies for rare genetic disorders. The business model of Vertex Pharmaceuticals Inc is based on researching and developing therapies for rare genetic disorders. The company collaborates closely with patients, leading scientists, and medical professionals to develop groundbreaking therapies. Vertex is a vertically integrated company, handling everything from research and development to production and marketing in-house. This allows the company to maintain control over the entire development and production process to ensure the highest quality products. Vertex is divided into different divisions to organize its activities. The Paris research facility specializes in the development of therapies for cystic fibrosis and other rare genetic disorders. The San Diego facility focuses on the development of treatments for cancer. Additionally, the company maintains research facilities in the UK and Canada. Vertex Pharmaceuticals Inc's most well-known product is Kalydeco, the first approved medication for the treatment of cystic fibrosis targeting a specific genetic mutation. Kalydeco aims to restore the function of a specific protein in the lungs, targeting the underlying cause of the disease. The company has also developed other therapies for cystic fibrosis, including Orkambi and Symdeko, which also target genetic mutations. Vertex also has therapies for cancer in its portfolio, such as the drug VX-970 currently in clinical trials for cancer treatment. In summary, Vertex Pharmaceuticals Inc is a leading biopharmaceutical company focused on developing therapies for rare genetic disorders. Since its founding in 1989, Vertex has continuously improved its technology and production capabilities, becoming one of the most innovative companies in the industry. The company is vertically integrated and consists of various research facilities dedicated to developing therapies for different diseases. Vertex has developed several groundbreaking medications for genetic disorders, including Kalydeco (the first approved medication for cystic fibrosis), Orkambi, and Symdeko. Vertex Pharmaceuticals Inc is an example of how research and development can play a significant role in treating rare diseases. Vertex Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Vertex Pharmaceuticals revenue by segment

In the annual report of the Vertex Pharmaceuticals share (US92532F1003, 882807, VRTX), it breaks down its revenues into 4 segments: 1. Symdeko, 2. Orkambi, 3. Kalydeco, 4. Trikafta. The Vertex Pharmaceuticals stock (WKN: 882807, ISIN: US92532F1003, Ticker Symbol: VRTX) is a leading investment for investors interested in participating in the Health Care sector.

  • 34 % Symdeko

  • 32 % Orkambi

  • 24 % Kalydeco

  • 10 % Trikafta

Debt Details

Understanding Vertex Pharmaceuticals's Debt Structure

Vertex Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Vertex Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Vertex Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Vertex Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Vertex Pharmaceuticals stock

What is the debt of Vertex Pharmaceuticals this year?

Vertex Pharmaceuticals has a debt level of -10,791.6 USD this year.

What was the debt of Vertex Pharmaceuticals compared to the previous year?

The debt of Vertex Pharmaceuticals has increased by 7.57% compared to the previous year increased.

What are the consequences of high debt for investors in Vertex Pharmaceuticals?

High debt can pose a risk for investors of Vertex Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Vertex Pharmaceuticals?

Low debt means that Vertex Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Vertex Pharmaceuticals affect the company?

An increase in debt of Vertex Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Vertex Pharmaceuticals affect the company?

A reduction in debt of Vertex Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Vertex Pharmaceuticals?

Some factors that can influence the debt of Vertex Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Vertex Pharmaceuticals so important for investors?

The debts of Vertex Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Vertex Pharmaceuticals take to change the debt?

To change the debt, Vertex Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Vertex Pharmaceuticals pay?

Over the past 12 months, Vertex Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vertex Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Vertex Pharmaceuticals?

The current dividend yield of Vertex Pharmaceuticals is .

When does Vertex Pharmaceuticals pay dividends?

Vertex Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vertex Pharmaceuticals?

Vertex Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Vertex Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vertex Pharmaceuticals located?

Vertex Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vertex Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vertex Pharmaceuticals from 10/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/13/2024.

When did Vertex Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/13/2024.

What was the dividend of Vertex Pharmaceuticals in the year 2023?

In the year 2023, Vertex Pharmaceuticals distributed 0 USD as dividends.

In which currency does Vertex Pharmaceuticals pay out the dividend?

The dividends of Vertex Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Vertex Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von Vertex Pharmaceuticals

Our stock analysis for Vertex Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vertex Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.